tepoditamab   Click here for help

GtoPdb Ligand ID: 10353

Synonyms: MCLA-117 | MCLA117 | PB9122
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds CLEC12A on myeloid cells and CD3ε on cytotoxic T cells. It is being developed by Merus as a novel therapy for acute myeloid leukemia (AML) [1].
Click here for help
Immunopharmacology Comments
CLEC12A is a myeloid differentiation antigen. It is expressed on 90-95% of newly diagnosed and relapsed AML, and is selectively expressed on leukemic stem cells but not on normal early hematopoietic progenitors. Targeting CLEC12A and CD3ε simultaneously with MCLA-117 is expected to kill both AML leukemic blasts and AML leukemic stem cells, including residual leukemic stem cells in bone marrow niche compartments [1].